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Abstract
SLAMF1 is often overexpressed in Epstein Barr virus (EBV)-infected B cell tumors. How-
ever, its role in the pathogenesis of EBV-infected B cell tumors remains largely unknown.
Here, we generated SLAMF1-deficient EBV+ tumor cells and examined the effect of its defi-
ciency on cell proliferation and cell survival. There were no significant differences in cell pro-
liferation and cell cycle distribution for short periods between the SLAMF1-deficient and
wild-type cells. However, the deficient cells were more resistant to an AKT inhibitor (MK-
2206). When the both cells were co-cultured and repeatedly exposed to the limitations in
nutrition and growth factors, the SLAMF1-deficient cells were gradually decreased. We
observed that levels of phospho-AKT were differentially regulated according to the nutri-
tional status between the SLAMF1-deficient and wild-type cells. A decrease in phospho-
AKT was observed in SLAMF1-deficient cells as well as an increase in pro-apoptotic Bim
just before cell passage, which may have been due to the loss of SLAMF1 under poor
growth condition. Overall, SLAMF1 is not a strong survival factor, but it seems to be neces-
sary for cell survival in unfavorable growth condition.
Introduction
Signaling lymphocyte activation molecule family member 1 (SLAMF1/CD150) is a self-ligand
receptor that is expressed on activated T- and B-lymphocytes, dendritic cells and macrophages
[1, 2]. Ligation of SLAMF1 on B cells enhances cell proliferation and apoptosis triggered by
the activation of CD40 and Fas/CD95, respectively [3, 4]. SLAMF1 also serves as a receptor for
measles virus and a phagocytic element for bacterial killing [1, 5–7]. SLAMF1 was differentially
expressed according to B cell developmental stages [8], NF-κB activation [9], or the cell of ori-
gin [10]. For instance, it was positive in activated B-cell-like (ABC) DLBCL, but not in germi-
nal center B-cell-like (GCB) DLBCLs [10]. SLAMF1 is highly induced in the Epstein Barr virus
(EBV)-infected lymphoblastoid cell lines (LCL) and the latency type III EBV+ lymphoma [9,
11]. We reported the overexpression of SLAMF1 and recurrent copy number gain at 1q23.3
harboring SLAMF1 in EBV+ DLBCL [12]. This suggests that SLAMF1 might play a role in the
pathogenesis of EBV+ DLBCL.
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SLAMF1 is a type I glycoprotein that consists of two Ig-like extracellular domains and a
cytoplasmic tail. Its cytoplasmic domain contains two immunoreceptor tyrosine-based switch
motifs (ITSMs) (TxYxxI/V) [1]. These switch motifs interact with several molecules that initi-
ate cell signaling. They include adaptor molecules SH2D1A (SAP) and SH2D1B (EAT-2), the
phosphatases SHP-2 and SHIP and the Src-family kinases Fyn, Lyn, and Fgr [1]. Positive or
negative signaling through SLAMF1 depends on type of molecules bind to it. Ligation of
SLAMF1 could activate the ERK and AKT signaling pathways [10, 13]. In tumor cells, ligation
of SLAMF1 resulted in transient phosphorylation of Akt or dephosphorylation depending on
cellular context [10]. However, the significance of the activation of these signaling pathways
remains to be explored.
To understand the possible role of SLAMF1 in EBV+ DLBCL, we depleted SLAMF1 in
EBV+ Farage cells and tested its effect on cell proliferation and survival. SLAMF1 was not nec-
essary for cell survival when cultured in optimal growth conditions, but it might be necessary
under unfavorable growth condition.
Materials and methods
Cell culture and reagents
Farage cells are an EBV+ B cell lymphoma cell line, which were purchased from ATCC (Amer-
ican Type Culture Collection, Manassas, VA, USA) and cultured in RPMI 1640 media contain-
ing 10% fetal bovine serum (FBS) and antibiotics (100 μg/mL penicillin and streptomycin) at
37˚C under a 5% CO2 humidified atmosphere. Cell line authentication and mycoplasma test-
ing were performed periodically in our institute.
Generation of SLAMF1-deficient Farage cells
SLAMF1-deficient Farage cells were generated by using the Guided it-CRISPR/Cas9 System
(Clontech Laboratories, Inc., Mountain View, USA). Oligomers for custom sgRNAs that target
exon3 of SLAMF1 were designed using on-line tools (http://crispr.mit.edu/) and cloned into
the pGuide-it vector according to company’s manual.
The sequences of sgRNA were as follows: 5'- CG GGA CCT GCA CCT TGA TAC-3'
and 5'- AT TCC CAG ACC TTC AGC CCG-3'. The cloned vectors were mixed with T
buffer (Lonza, Allendale, NJ, USA) and transfected into Farage cells by electroporation with
Nucleofector (Lonza, program S-018). Farage cells expressing Cas9 were selected using FACS
Aria III (BD Life Sciences, San Jose, CA, USA) 2 days after electroporation and were cloned by
serial dilution and FACS-mediated selection. Insertion or deletion mutations were screened
with GeneArt Genomic Cleavage Detection kit (Thermo Fisher Scientific, Waltham, MA,
USA) after PCR amplification of exon 3. The primer sequences for PCR were as follows:
EX3-fw, 5'-CCA TGT GAA GAC TGA GCC CAT G-3'; EX3-rev, 5'-CCA GGG GTT
CAC TTC AGT GAT G-3'. To identify nonsense or missense mutations, the PCR products
were directly sequenced or cloned using TOPO TA cloning kit and sequenced.
Fluorescence-activated cell sorting (FACS) analysis
SLAMF1-deficient and wild-type Farage cells were seeded at a density of 2 × 105/mL cells in
T25 flasks and cultured for 2 days. Then, 1 × 106 cells were then washed, and their Fc receptors
were blocked with TruStain (Biolegend, San Diego, CA, USA). Cells were labeled with FITC-
conjugated IgG or anti-human SLAMF1/CD150 antibody (Cat# 306306, Biolegend, San
Diego, CA, USA) and were subject to fluorescence-activated cell sorting (FACS) analysis by a
Becton-Dickinson FACS Calibur (Franklin Lakes, NJ, USA).
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Drug inhibition experiments
SLAMF1-deficient and wild-type Farage cells were seeded at a density of 2 × 104 cells in
96-well plates. Cells were treated with various concentrations of MK-2206 (Selleckchem,
Houston, TX, USA) for 3 days. Cell proliferation and viability were measured using the WST-
1 reagent according to the manufacturer’s protocols (Roche, Indianapolis, IN). Optical density
was measured at 450 and 600 nm 4 h after the addition of the WST-1 reagent. The concentra-
tion to reduce cell viability by 50% (IC50) was calculated using package drc (http://cran.r-
project.org/web/packages/drc/). We used the 3-parameter logistic function standard curve
analysis for dose response.
Cell proliferation and cell cycle analysis
Cell proliferation was accessed by counting viable cells at 1, 3, and 5 days after seeding at
1 × 105/mL cells. For the cell cycle analysis, Farage cells were washed with cold 1 × PBS and
then fixed with 70% cold ethanol for more than 30 min at -20˚C. Cells were washed with
1 × PBS and incubated with a staining solution including 50 μg/mL propidium iodide (PI) and
200 μg/mL RNase A for 15 min at 37˚C. DNA content was analyzed using a Becton-Dickinson
FACS Calibur flow cytometer. Data were analyzed with CellQuest software (Becton Dickinson,
Heidelberg, Germany).
Immunoblot analysis
The SLAMF1 wild-type and mutant Farage cells were lysed with M-PER buffer (Pierce Bio-
technology, Rockford, IL) containing a 1× protease and phosphatase inhibitor cocktail
(Roche). Then, 20–40 μg of lysate was separated on 4–15% or 12% precast sodium dodecyl sul-
fate-polyacrylamide gels and transferred onto polyvinylidene fluoride membranes (Bio-Rad
Laboratories, Hercules, CA). The membranes were blocked with 5% non-fat dry milk and
incubated with appropriate primary and secondary antibodies. Signals were detected using the
SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology). The following
antibodies were used in this study: phospho-NF-kB p65 (3033), BCL-XL (2764), MCL1 (5453),
Bcl-2 (4223), Bim (2933), HSP70 (4782), phospho-AKT (4060) and panAKT (4691) were pur-
chased from Cell Signaling Technologies (Beverly, MA); LMP1 (CS1-4, M0897) from Dako
(Glostrup, Denmark); GAPDH (sc-25778), and goat anti-rabbit IgG (sc-3837) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). We developed an anti-SLAMF1 rabbit polyclonal
antibody for western blotting.
Analysis of apoptosis
SLAMF1 mutant and wild-type Farage cells were seeded at 2×105 cells/mL and cultured for 5
days. Cells were washed with 1× PBS and stained with fluorescein isothiocyanate (FITC)-con-
jugated anti- Annexin V antibody (BD Biosciences, Heidelberg, Germany) and propidium
iodide (PI) (Sigma Aldrich, St. Louis, MO, USA). Detection of early apoptotic (Annexin
V-FITC+ and PI-) and late apoptotic cells (Annexin V-FITC+ and PI+) was performed using a
FACS Calibur (Becton and Dickinson). Data were analyzed with CellQuest software (Becton
Dickinson).
Statistical analysis
All data were analyzed with the statistical program GraphPad Prism 6.0 (San Diego, CA). Stu-
dent’s t-test was used to determine the statistical significance of differences between groups.
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Results
Generation of SLAMF1-deficient Farage cells
SLAMF1 was highly expressed in Farage cells, which is an EBV positive B cell lymphoma cell
line. To generate SLAMF1-deficient Farage cells, we designed two sgRNAs targeting exon 3 of
SLAMF1 by using CRISPR/Cas9 technology (Fig 1A). The two sgRNAs coupled with Cas9
expression vectors were transfected, and three cell lines named 3C, 8C and 4E were obtained
by serial dilution and mutational analysis (Fig 1B). As shown in Fig 1B, two bands were
observed in 4E after PCR amplification, indicating a deletion of exon 3 in one allele (Fig 1B).
Sub-bands appeared after cleavage of heteroduplex in 3C, 8C and 4E, indicating the presence
of at least one indel mutation (Fig 1B). We next tested whether expression level of SLAMF1
was decreased at the cell surface by using FACS analysis. SLAMF1 was almost negative in the
three cell lines compared with SLAMF1 wild-type Farage cells (Fig 1C). This result was further
confirmed by western blot analysis with the anti-human SLAMF1 antibody, which was a
Fig 1. SLAMF1-deficient Farage cells were cloned by using CRISPR/Cas9. (A) The two regions on exon 3 indicate two sgRNA
sites of SLAMF1. The two regions outside of exon 3 indicate two primer sites for PCR amplification (upper panel). Indel mutations
were confirmed with sequencing and are depicted in the lower panel. (B) Genomic DNA isolated from the selected clones was
PCR-amplified. The PCR products were denatured and digested after allowing for the formation of duplexes. Cleaved DNAs were
analyzed on 2% agarose gel. (C) SLAMF1 on the cell surface of wild-type and mutant Farage cells were analyzed by FACS. The left
peak indicates Farage cells labeled with FITC-anti-IgG antibody, whereas a right peak indicates Farage cells labeled with a FITC-
anti-SLAMF1 antibody. The SLAMF1 mutant Farage cells overlap with the left peak (depicted in red). (D) A depletion of SLAMF1
was confirmed by western blot for SLAMF1, LMP1, phosphor-AKT (S473) and GAPDH.
https://doi.org/10.1371/journal.pone.0238791.g001
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different clone than that used for FACS analysis. SLAMF1 was not detected or remarkably
decreased in mutant cell lines, whereas LMP1 had no discernable change between SLAMF1
wild-type and mutant cells (Fig 1D). Of note, phospho-ATP was variable between them, sug-
gesting that the deficiency of SLAMF1 disturbs the AKT signaling pathway.
Differential response to an AKT inhibitor
SLAMF1 was implicated as a co-stimulatory molecule for cell proliferation and cell death.
Therefore, we performed cell proliferation assay by counting cells for 5 days (Fig 2A). There
was no significant difference in cell proliferation among the four cell lines. Next, cell cycle
analysis was performed by using FACS. Similarly, there was no significant difference in cell
cycle distribution among the cell lines (Fig 2B). We observed overexpression of SLAMF1 at the
cell surface of drug resistant Farage cells [14]. We therefore tested whether SLAMF1-deficient
Farage cells responded differentially to drugs targeting several pathways. A differential
response was observed only in cells treated with an AKT inhibitor (MK-2206) among the
Fig 2. Comparison of SLAMF1 wild-type and SLAMF1-deficient cell proliferation. (A) The effect of SLAMF1 on cell proliferation
was assessed by counting viable cells for 5 days. (B) The cell cycle distribution was analyzed by using FACS. Cells fixed with 70%
ethanol were stained with propidium iodide (PI) and subject to FACS analysis based on the DNA content. (C) Cells were incubated
with various concentrations of AKT inhibitor MK-2206 for 3 days. Cell proliferation was assessed with WST-1 reagent. The Y-axis
indicates viability (%). IC50 of the 3C, 8C, 4E and WT cells were 7.6, 7.9, 3.7 and 1.05 μM.
https://doi.org/10.1371/journal.pone.0238791.g002
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drugs tested. For MK-2206, IC50 of the mutant cells 3C, 8C and 4E were 7.6, 7.9 and 3.7 μM,
respectively, whereas IC50 of WT cells were 1.05 μM (Fig 2C). The mutant cells exhibited more
resistance to MK-2206 compared with WT cells. In addition to variable phospho-AKT levels
(Fig 1D), this result suggested that loss of SLAMF1 might affect the AKT signaling pathway.
Loss of SLAMF1 affects AKT and Bim
When we were trying to clone the SLAMF1-deficient Farage cells, we observed that SLAMF1
wild-type Farage cells often out-competed the SLAMF1-deficient cells (Fig 3A). Therefore, we
mixed both wild-type and mutant SLAMF1 Farage cells and cultured them together for more
than one month with repeated passages every 5 and 7 days. One mutant cell (8C) was gradually
out-competed after the 5-day cell passages for one month, whereas two other mutant cells (3C
and 4E) were more clearly out-competed by the 7-day cell passages by wild-type cells, which
then dominated the mixed cell population (Fig 3B). We observed that before the cell passages
wild-type cells were kept aggregated together, whereas a part of the SLAMF1-deficient cells
became separated (Fig 4A). We hypothesized that some SLAMF1-deficient cells might be less
tolerant to nutritional deficiency or acidic microenvironment and undergo programmed cell
death. We analyzed apoptotic cells with FACS after labeling cells with Annexin V plus 7-AAD.
We found that late apoptotic cells were increased in all SLAMF1-deficient cells (Fig 4B). We
then performed a western blot analysis for phospho-AKT and anti- or pro-apoptotic genes at 2
and 5 days after passaging. Interestingly, phospho-AKT was higher in SLAMF1-deficient cells
than in wild-type cells at day 2 (3C and 8C) (Fig 4C), whereas it was much lowered at day 5
(Fig 4C). The level of phospho-NF-kB p65 was greatly decreased at day 5 when compared to
day 2, but no apparent differences were seen between wild-type and mutant cells. The pro-apo-
ptotic gene Bim seemed to be counterbalanced by MCL1 and Bcl-XL as shown in the 3C line
at day 2. Bim was increased in SLAMF1-deficient cells without an increase in MCL1 at day 5.
The balance between anti- or pro-apoptotic genes seemed to shift towards pro-apoptosis due
to the increased Bim at day 5, which might be responsible for the increased apoptosis in the
mutant cells.
Discussion
In this study, we observed that under optimal growth conditions, a deficiency of SLAMF1
made no discernible differences in cell proliferation and cell cycle distribution in EBV+ Farage
cells. However, when the Farage cells were exposed to limited nutrition and growth factors,
SLAMF1 was required to evade apoptosis through the activation of AKT.
Evading apoptosis is one of the characteristics acquired by cancer cells [15]. EBV suppresses
apoptosis of EBV-infected B cells by several mechanisms. First, the EBV latent membrane pro-
tein LMP1 activates classical or non-classical NF-κB pathway, which results in an increase of
the anti-apoptotic gene Bcl-xL and survivin [16]. Secondly, EBV down-regulates the pro-apo-
ptotic gene Bim. EBV-infected B cells down-regulate Bim [17]. Especially, EBV nuclear pro-
teins EBNA3A and 3C repress the transcription of Bim by recruiting polycomb repressive
complex 2 (PRC2) [18] and chromatin remodeling. EBV’s clustered multiple miRNAs attenu-
ate Bim [19]. Bim was significantly downregulated in EBV-positive compared to EBV-negative
posttransplant lymphoproliferative disorders (PTLD) [20]. The reason why Bim is a target of
EBV is that Bim is responsible for cell death by depriving survival factors as demonstrated in
many cells originating from the hematopoietic lineage [21–26]. Therefore, loss of Bim renders
cells resistant to apoptosis induced in vitro by cytokine or growth factor deprivation even in a
B cell lymphoma model [27]. In Fig 4, we observed increased Bim levels in SLAMF1-deficient
cells at day 5 when cytokines or growth factors were not be sufficient for survival, but not in
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SLAMF1 wild-type Farage cells. We also observed a reverse relationship between phospho-
AKT and Bim, which provided clues for how Bim might be regulated in Farage cells [22, 28].
The activated AKT phosphorylates FOXO3, which renders FOXO3 sequestered in cytosol,
thereby inhibiting transcription of a pro-apoptotic gene Bim by FOXO3. Taken together, we
Fig 3. Outgrowth of SLAMF1 wild-type cells over mutant cells during long-term co-culture. (A) Proportion of
wild-type cells that were gradually increased when 4E cells had been contaminated with wild-type cells at the initial
cloning stage. (B) SLAMF1 wild-type cells and mutant cells were mixed at a 1:1 ratio at day 0. During the first one
month, the cells were subcultured every 5 days, and then the next month, the cells were subcultured every 7 days.
Wild-type cells became dominant in all three mutant cell lines as the interval between cell passages increased.
https://doi.org/10.1371/journal.pone.0238791.g003
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speculate that SLAMF1 regulates the AKT pathway, which leads to suppression of Bim to
evade apoptosis under unfavorable growth conditions.
SLAMF1 was known to costimulate proliferation of activated B cells [3]. In a previous study
[14], we used SLAMF1 as a surrogate marker for LMP1 and observed that the SLAMF1high
cells grew faster than the SLAMF1low cells. However, loss of SLAMF1 itself did not obviously
alter cell proliferation and cell cycle distribution at the exponential growth phase. This indi-
cated that other factors such as LMP1, which is epistatic to SLAMF1, play a major role in the
proliferation of Farage cells. Unexpectedly, we repeatedly observed that the SLAMF1 mutant
cells (3C and 8C) proliferated faster in the presence of an allosteric AKT inhibitor (MK-2206)
at a low dose compared to SLAMF1 wild-type cells (Fig 2C). We cannot fully explain this
result; however, different levels of activated AKT might explain the underlying mechanism of
this result. The greater amount of activated AKT was seen in 3C and 8C mutant cells compared
to wild-type cells at day 2 (Figs 1 and 4). Therefore, MK-2206 might not fully inhibit AKT
phosphorylation at the same amount that can inhibit AKT in wild-type cells. This result
implies that SLAMF1 might down-regulate the AKT pathway under optimal growth
conditions.
The relative amount of phospho-AKT in SLAMF1 mutant vs. wild type cells was reversed
between days 2 and 5 in our experiment (Fig 4). It was questioned how SLAMF1 functions as a
costimulatory molecule in opposite cellular events of cell proliferation and apoptosis [11]. This
contradictory function is thought to be attributable to its cytoplasmic domain with two ITSM
Fig 4. Increase of Bim might underlie slightly increased apoptosis in SLAMF1 mutant cells at day 5. (A) Cell images of SLAMF1 wild-
type and mutant (8C) cells at day 5. Wild-type cells were kept aggregated together, whereas mutant cells became separated. (B) Analysis of
apoptotic cells using FACS after staining cells with anti-Annexin V and propidium iodide (PI). Double positive region (upper right) indicates
late apoptotic cells (Annexin V-FITC+ and PI+). (C) SLAMF1 mutant and wild-type Farage cells were seeded at 2×105 cells/mL and lysed 2
and 5 days after culture. Western blotting for phospho-AKT (S473), phospho-NF-kB p65, BCL2, MCL1, BCL-xL, and Bim at days 2 and 5.
https://doi.org/10.1371/journal.pone.0238791.g004
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that interact with several molecules such as the adaptors SAP and EAT-2, SHIP, SHP-1, Lyn,
and PI3K [1, 10]. Although the molecules that are recruited to these motifs at days 2 and 5
have not yet been identified, SLAMF1 might recruit phosphatases such as SHP-2 and SHIP or
kinases to its cytoplasmic tail to maintain optimal strength of the AKT signaling pathway
required for proliferation and survival in Farage cells. In conclusion, SLAMF1 is not a strong
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